Abstracts tagged "B-Cell Targets"

Abstract Number: 1646 • ACR Convergence 2024
A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE
Iolanda Miceli¹, Rochelle Sherlock², Pamela Hall², IanIan Cheang², Akshay D'Cruz³, Taylah Bennett², Terry Lim Kam Sian², Rangi Kandane-Rathnayake⁴, Eric Morand⁵ and Sarah Jones², ¹Monash University, Glen Iris, Victoria, Australia, ²Monash University, Melbourne, Australia, ³Monash University, Me, Australia, ⁴Monash University, Clayton, Victoria, Australia, ⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: SLE is primarily mediated by B cell dysregulation on a background of type I interferon (IFN) activation. This multi-faceted nature of immune defects in…
Abstract Number: 2437 • ACR Convergence 2024
Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE
Changming Lu¹, Jose Rubio², Hui-Chen Hsu¹ and John D. Mountz³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Hoover, AL, ³University Alabama Birmingham, Birmingham, AL
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an increase in T-bet+ IgD−CD27− double negative 2 (DN2) B cells, attributed to heightened TLR7 signaling. Identifying…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 0776 • ACR Convergence 2024
Follicular Dendritic Cell PD-L1 Expression Promotes Autoreactive Germinal Center Formation
Elliot Akama-Garren¹, Yingying Zhang², Balthasar Heesters³, Padraic Fallon⁴ and Michael Carroll², ¹Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Utrecht University, Utrecht, Netherlands, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Germinal center (GC) responses generate humoral immunity through coordinated interactions between B cells and T follicular helper (TFH) and T follicular regulatory (TFR) cells.…
Abstract Number: 1651 • ACR Convergence 2024
Unlocking the Secrets of Breg Dysfunction in Lupus: Glycosylation Patterns as Therapeutic Targets
Pauline Kerleroux-Trébaol¹, Marie Morel¹, Sandrine Jousse-Joulin², Divi Cornec³, Pierre Pochard¹ and Anne Bordron¹, ¹Université de Bretagne Occidentale, brest, France, ²cavale blanche hospital, brest, France, ³Service de Rhumatologie, CHU de Brest, Brest, France
Background/Purpose: The immune system is a complex network of cells preventing the invasion of the organism from external particles. The break in the homeostasis will…
Abstract Number: 2548 • ACR Convergence 2024
NADPH Oxidase in B Cells and Macrophages Protects Against Murine Lupus by Regulation of TLR7
Rachael Gordon¹, Haylee Cosgrove², Anthony Marinov³, Sebastien Gingras¹, Jeremy Tilstra², Allison Campbell⁴, Sheldon Bastacky¹, Andras Perl⁵, Kevin Nickerson¹ and Mark Shlomchik², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh, Homestead, PA, ⁴Yale, New Haven, ⁵SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by loss of tolerance to nuclear antigens, immune activation, and organ damage. Loss of…
Abstract Number: 0010 • ACR Convergence 2024
Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Holly Wobma¹, Francesca Alvarez-Calderon², Jiayi Dong², Alexandre Albanese², Kayleigh Omdahl², Rene Bermea³, Gillian Selig⁴, Marlana Winschel², Elisa Rojas Palato², Katherine Michaelis¹, Xianliang Rui², Bruce Blazar⁵, Susan Prockop², Victor Tkachev³, Ulrike Gerdemann² and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ⁴Harvard College, Boston, MA, ⁵Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN
Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
Abstract Number: 0777 • ACR Convergence 2024
Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
Theodoros Ioannis Papadimitriou¹, Jing Jing Wang², Xuehui He³, Sidney van der Zade⁴, Massis Krekorian⁵, Prashant Singh⁶, Erik Dik⁵, Ger Pruijn⁵, Tom Gordon², Hans Koenen⁷, Martijn Huijnen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Flinders University, Adeleide, Australia, ³Radboudumc, Nijmegen, Netherlands, ⁴Radboudumc, Amsterdam, Netherlands, ⁵Radboudumc, Nijmegen, Gelderland, Netherlands, ⁶Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic inflammatory disorder, characterized by formation of autoantibodies. Over time rheumatoid factor (RF) clones can give rise to cryoglobulinemic…
Abstract Number: 1733 • ACR Convergence 2024
Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Saira Sheikh¹, Tahseen Mozaffar², Vimal Derebail¹, Natalie Grover¹, Jonathan Hogan³, Courtney Little³, Yvonne White³, Claire Miller³, Rebecca Estremera³, Jenell Volkov³, Daniel Nunez³, Jason Stadanlick³, Mallorie Werner³, Zachary Vorndran³, Alexandra Ellis³, Jazmean Williams³, Justin Cicarelli³, Quynh Lam³, thomas Furmanak³, Chris Schmitt³, Fatemeh Nezhad³, Dan Thompson³, Samik Basu³ and David Chang³, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Irvine, Irvine, CA, ³Cabaletta Bio, Philadelphia, PA
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
Abstract Number: 2598 • ACR Convergence 2024
p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
Zhihua Ma, Luis Carvajal, Andrew Chen, Rosa Villagomez, Yare calderon, Tamara Hopkins, Hua Gao, Benjamin Trotter, Charles Lin and Peter Rahl, Kronos Bio, Cambridge, MA
Background/Purpose: Across inflammatory and autoimmune diseases, pathologic signaling converges in the nucleus to elevate transcription of numerous inflammatory effectors such as cytokines, chemokines and antibodies.…
Abstract Number: 0011 • ACR Convergence 2024
Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Brandon Kwong¹, Daniel Anaya¹, Soo Park², Sunetra Biswas², Jeevitha Jeevan², Jesus Banuelos², Madison Strobach², Nicole Khoshnoodi¹, Timothy Klasson¹, Santiago Foos-Russ¹, Jennifer Zeng¹, Candice Gibson³, Jazmin Bravo², Simone Sandoval¹, Shouvonik Sengupta¹, Shairaz Shah¹, Tom Van Blarcom² and Karen Walker², ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emeryville, ³Kyverna Therapeutics, Inc., Emerybille
Background/Purpose: Apheresis in conventional chimeric antigen receptor (CAR) T-cell therapy can be burdensome, and conventional manufacturing cultures apheresis-derived cells for 7-14 days, leading to a…
Abstract Number: 0778 • ACR Convergence 2024
Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease
Justin Chou¹, Ricardo Grieshaber-Bouyer², Michelle J Wu³, Christina Bergmann², Jule Taubmann⁴, Fabian Müller⁵, Aline Bozec⁴, Tobias Rothe², Andreas MAckensen⁶, Amber Podoll⁷, Jonathan Gutman⁷, Aiden Haghikia⁸, Dimitrios Mougiakakos⁹, Gary Tong³, Pouya Kheradpour³, Francis Kim¹⁰, Prameela Ramesan¹⁰, Brandon Kwong¹⁰, Kunbin Qu¹⁰, Bishwa Ganguly¹⁰, Dominic Borie¹⁰, James Chung¹⁰ and Georg Schett¹¹, ¹Kyverna Therapeutics, Emeryville, CA, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Verily Life Sciences, South San Francisco, CA, ⁴Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁶Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, CO, ⁸Otto-von-Guericke University, Magdeburg, Germany, ⁹Otto-von-Guericke University, Magdeburg, Germany, Magdeburg, Germany, ¹⁰Kyverna Therapeutics, Inc., Emeryville, CA, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy represents a promising advancement in the treatment of autoimmune diseases, including systemic sclerosis (SSc), idiopathic inflammatory myopathy…
Abstract Number: 1749 • ACR Convergence 2024
Safety and Long-term Efficacy of CD19-CAR T-cell Therapy in 30 Patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Carlo Tur¹, Tobias Krickau³, Markus Metzler⁴, Laura Bucci¹, Christina Bergmann⁵, Janina Auth¹, Jule Taubmann⁶, Panagiotis Garantziotis⁷, Sebastian Boeltz⁸, Soraya Kharboutli⁹, Silvia Spoerl⁹, Simon Völkl¹⁰, Michael Aigner⁹, Sascha Kretschmann⁹, Ingrid Vasova⁹, Andreas MAckensen¹¹, Ricardo Grieshaber-Bouyer⁸ and Georg Schett¹², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Pediatrics and Adolscent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁴Department of Pediatrics and Adolscent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁶Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁸Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ¹⁰Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ¹¹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Treating autoimmune diseases like Systemic Lupus erythematosus (SLE), Idiopathic Inflammatory Myositis (IIM) or Systemic Sclerosis (SSc) is challenging and often requires life-long immunosuppressive therapy.…
Abstract Number: 2663 • ACR Convergence 2024
ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Monica Moreno, Shon Green, Kevin P. Nishimoto, Jackie Kennedy-Wilde, Taylor Barca, Melinda Au, Simona Costanzo, Gregory Vosganian, Benjamin Hsu, Francesco Galimi and Blake T. Aftab, Adicet Therapeutics, Inc., Redwood City, CA
Background/Purpose: γδ T cells serve a role in immune surveillance and their capability to traffic to tissues is fundamental to their natural biology1. They are…
Abstract Number: 0013 • ACR Convergence 2024
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Jordan Anderson², Nathan Rollins², Tobias Green², Agustin Plasencia², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting immune cell responses that cause tissue damage in autoantibody-mediated diseases such as idiopathic inflammatory myopathies, lupus…

« Previous Page
1
…
7
8
9
10
11
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].